373 related articles for article (PubMed ID: 26183802)
1. Utility-based criteria for selecting patients with hepatocellular carcinoma for liver transplantation: A multicenter cohort study using the alpha-fetoprotein model as a survival predictor.
Vitale A; Farinati F; Burra P; Trevisani F; Giannini EG; Ciccarese F; Piscaglia F; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Cabibbo G; Felder M; Sacco R; Morisco F; Missale G; Foschi FG; Gasbarrini A; Svegliati Baroni G; Virdone R; Chiaramonte M; Spolverato G; Cillo U;
Liver Transpl; 2015 Oct; 21(10):1250-8. PubMed ID: 26183802
[TBL] [Abstract][Full Text] [Related]
2. Delta-slope of alpha-fetoprotein improves the ability to select liver transplant patients with hepatocellular cancer.
Lai Q; Inostroza M; Rico Juri JM; Goffette P; Lerut J
HPB (Oxford); 2015 Dec; 17(12):1085-95. PubMed ID: 26373980
[TBL] [Abstract][Full Text] [Related]
3. α-Fetoprotein is a potential survival predictor in hepatocellular carcinoma patients with hepatitis B selected for liver transplantation.
Zhang Q; Shang L; Zang Y; Chen X; Zhang L; Wang Y; Wang L; Liu Y; Mao S; Shen Z
Eur J Gastroenterol Hepatol; 2014 May; 26(5):544-52. PubMed ID: 24614696
[TBL] [Abstract][Full Text] [Related]
4. The relative net health benefit of liver resection, ablation, and transplantation for early hepatocellular carcinoma.
Spolverato G; Vitale A; Ejaz A; Kim Y; Maithel SK; Cosgrove DP; Pawlik TM
World J Surg; 2015 Jun; 39(6):1474-84. PubMed ID: 25665675
[TBL] [Abstract][Full Text] [Related]
5. Identifying patients at higher risk of hepatocellular carcinoma recurrence after liver transplantation in a multicenter cohort study from Argentina.
Piñero F; Marciano S; Anders M; Orozco Ganem F; Zerega A; Cagliani J; Andriani O; de Santibañes E; Gil O; Podestá LG; McCormack L; Gadano A; Silva M
Eur J Gastroenterol Hepatol; 2016 Apr; 28(4):421-7. PubMed ID: 26684693
[TBL] [Abstract][Full Text] [Related]
6. Serological Risk Index Based on Alpha-Fetoprotein and C-Reactive Protein to Indicate Futile Liver Transplantation Among Patients with Advanced Hepatocellular Carcinoma.
Kornberg A; Schernhammer M; Kornberg J; Friess H; Thrum K
Dig Dis Sci; 2019 Jan; 64(1):269-280. PubMed ID: 30259282
[TBL] [Abstract][Full Text] [Related]
7. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
[TBL] [Abstract][Full Text] [Related]
8. AFP level and histologic differentiation predict the survival of patients with liver transplantation for hepatocellular carcinoma.
Yaprak O; Akyildiz M; Dayangac M; Demirbas BT; Guler N; Dogusoy GB; Yuzer Y; Tokat Y
Hepatobiliary Pancreat Dis Int; 2012 Jun; 11(3):256-61. PubMed ID: 22672818
[TBL] [Abstract][Full Text] [Related]
9. Combined Hangzhou criteria with neutrophil-lymphocyte ratio is superior to other criteria in selecting liver transplantation candidates with HBV-related hepatocellular carcinoma.
Xiao GQ; Yang JY; Yan LN
Hepatobiliary Pancreat Dis Int; 2015 Dec; 14(6):588-95. PubMed ID: 26663006
[TBL] [Abstract][Full Text] [Related]
10. A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list.
Vitale A; Volk ML; De Feo TM; Burra P; Frigo AC; Ramirez Morales R; De Carlis L; Belli L; Colledan M; Fagiuoli S; Rossi G; Andorno E; Baccarani U; Regalia E; Vivarelli M; Donataccio M; Cillo U;
J Hepatol; 2014 Feb; 60(2):290-7. PubMed ID: 24161408
[TBL] [Abstract][Full Text] [Related]
11. Is resectable hepatocellular carcinoma a contraindication to liver transplantation? A novel decision model based on "number of patients needed to transplant" as measure of transplant benefit.
Vitale A; Cucchetti A; Qiao GL; Cescon M; Li J; Ramirez Morales R; Frigo AC; Xia Y; Tuci F; Shen F; Cillo U; Pinna AD
J Hepatol; 2014 Jun; 60(6):1165-71. PubMed ID: 24508550
[TBL] [Abstract][Full Text] [Related]
12. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria.
Duvoux C; Roudot-Thoraval F; Decaens T; Pessione F; Badran H; Piardi T; Francoz C; Compagnon P; Vanlemmens C; Dumortier J; Dharancy S; Gugenheim J; Bernard PH; Adam R; Radenne S; Muscari F; Conti F; Hardwigsen J; Pageaux GP; Chazouillères O; Salame E; Hilleret MN; Lebray P; Abergel A; Debette-Gratien M; Kluger MD; Mallat A; Azoulay D; Cherqui D;
Gastroenterology; 2012 Oct; 143(4):986-94.e3; quiz e14-5. PubMed ID: 22750200
[TBL] [Abstract][Full Text] [Related]
13. Predictive Value of Alpha-fetoprotein in the Survival of Living Donor Liver Transplantation Recipients for Hepatocellular Carcinoma.
Jiang L; Liao A; Yan L; Li B; Zhu W; Wen T
Hepatogastroenterology; 2014 May; 61(131):747-51. PubMed ID: 26176068
[TBL] [Abstract][Full Text] [Related]
14. Patient Selection by Tumor Markers in Liver Transplantation for Advanced Hepatocellular Carcinoma.
Lee HW; Song GW; Lee SG; Kim JM; Joh JW; Han DH; Kim SI; Kim SH; Kim DS; Cho JY; Suh KS
Liver Transpl; 2018 Sep; 24(9):1243-1251. PubMed ID: 29575509
[TBL] [Abstract][Full Text] [Related]
15. Predicting survival after liver transplantation using up-to-seven criteria in patients with hepatocellular carcinoma.
de Ataide EC; Garcia M; Mattosinho TJ; Almeida JR; Escanhoela CA; Boin IF
Transplant Proc; 2012 Oct; 44(8):2438-40. PubMed ID: 23026614
[TBL] [Abstract][Full Text] [Related]
16. Section 5. Further expanding the criteria for HCC in living donor liver transplantation: when not to transplant: SNUH experience.
Lee KW; Yi NJ; Suh KS
Transplantation; 2014 Apr; 97 Suppl 8():S20-3. PubMed ID: 24849825
[TBL] [Abstract][Full Text] [Related]
17. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.
Notarpaolo A; Layese R; Magistri P; Gambato M; Colledan M; Magini G; Miglioresi L; Vitale A; Vennarecci G; Ambrosio CD; Burra P; Di Benedetto F; Fagiuoli S; Colasanti M; Maria Ettorre G; Andreoli A; Cillo U; Laurent A; Katsahian S; Audureau E; Roudot-Thoraval F; Duvoux C
J Hepatol; 2017 Mar; 66(3):552-559. PubMed ID: 27899297
[TBL] [Abstract][Full Text] [Related]
18. Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety.
Vitale A; Volk ML; Pastorelli D; Lonardi S; Farinati F; Burra P; Angeli P; Cillo U
Hepatology; 2010 Jan; 51(1):165-73. PubMed ID: 19877181
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of liver resection versus transplantation for early hepatocellular carcinoma within the Milan criteria.
Lim KC; Wang VW; Siddiqui FJ; Shi L; Chan ES; Oh HC; Tan SB; Chow PK
Hepatology; 2015 Jan; 61(1):227-37. PubMed ID: 24638991
[TBL] [Abstract][Full Text] [Related]
20. Hepatocyte nuclear factor 1β is a novel prognostic marker independent of the Milan criteria in transplantable hepatocellular carcinoma: a retrospective analysis based on tissue microarrays.
Shim JH; Lee HC; Han S; Kang HJ; Yu E; Lee SG
Liver Transpl; 2013 Mar; 19(3):336-45. PubMed ID: 23203386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
